Has James Clark received payments from drug or device companies?

Yes. Drug and device makers reported $2,989 in general payments to James Clark across 156 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Clark did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Clark come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Clark

Rheumatology · Evans, GANPI 1154954758

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 32.9% of the total. Reporting peaked in 2022 at $1,171 and has fallen 85.5% since, to $170 in 2024. That places this record below the midpoint for rheumatology clinicians in GA, where the typical reported total is $5,560.

$2,989in general payments, 2019–2025

Across 156 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$984
Amgen$833
UCB, Inc.$238
Lilly USA, LLC$191
GSK$150
Biodelivery Sciences International, Inc.$123
plus $470 from 16 others

What the payments were for

Food & beverage$2,975100%
Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	61	$984
Amgen	37	$833
UCB, Inc.	7	$238
Lilly USA, LLC	9	$191
GSK	8	$150
Biodelivery Sciences International, Inc.	10	$123
Novartis	4	$72
Fresenius Kabi USA, LLC	2	$48
Almatica Pharma LLC	2	$42
Mallinckrodt Hospital Products Inc.	2	$39
Sobi, Inc	2	$36
AstraZeneca	2	$36
Johnson & Johnson	1	$26
Actelion Pharmaceuticals US, Inc.	1	$25
Orthogenrx Inc.	1	$22
Pfizer	1	$22
E.r. Squibb & Sons, L.L.C.	1	$21
Boehringer Ingelheim	1	$21
Qiagen, LLC	1	$16
Collegium Pharmaceutical, Inc.	1	$15
Avanos Medical	1	$15
Arbor Pharmaceuticals, Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

EVENITY$125

How this compares

$2,989 in reported general payments places this provider in the 40th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia →

Other rheumatology in Evans

James MossellTifton$1.6M
Gary MyersonAtlanta$1M
Theresa Lawrence FordLawrenceville$410K
William WilsonAtlanta$344K
Jefrey LiebermanDecatur$247K
Mohammed AbubakerMarietta$218K
James HuntThomasville$160K
Omar KhanCumming$145K
Paul SutejAtlanta$140K
Sung LimAtlanta$125K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →